Form 4: NewAmsterdam Pharma Director Receives Equity Grants

NewAmsterdam Pharma's Director, Louis G. Lange, reported the acquisition of 3,400 restricted stock units and 15,300 stock options, alongside a correction to previously reported share ownership.

Summary

• Director Louis G. Lange acquired 3,400 Restricted Stock Units (RSUs) on January 7, 2026, each representing a contingent right to receive one ordinary share.
• These RSUs will vest on the one-year anniversary of the vesting start date, subject to continued service through such date.
• Lange also acquired 15,300 stock options on January 7, 2026, with an exercise price of $35.45.
• The ordinary shares underlying these options will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to continued service.
• A correction was made regarding 3,102 ordinary shares issued from RSU vesting on March 28, 2025, which were inadvertently reported as direct holdings but are indirectly held by LGLange III Trust DTD10.

Sentiment

Score: 7

Explanation: The filing reports routine equity grants to a director, which are generally positive for aligning interests. The correction of a minor reporting error is a neutral to slightly negative procedural item, but the overall sentiment is positive due to the incentive alignment.

Positives

• Director Louis G. Lange received 3,400 Restricted Stock Units (RSUs) as part of his compensation, aligning his interests with shareholders.
• Lange was granted 15,300 stock options with an exercise price of $35.45, providing a long-term incentive for performance.

Negatives

• An inadvertent reporting error occurred where 3,102 ordinary shares were incorrectly reported as direct holdings instead of indirect holdings, requiring a correction.

Future Outlook

The vesting schedules for the granted RSUs and stock options indicate a long-term commitment from Director Louis G. Lange, aligning his future incentives with the company's performance over the next one to ten years.

Industry Context

Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industry to attract and retain experienced leadership, aligning their long-term interests with shareholder value creation. The specific terms of these grants reflect typical compensation structures for board members in publicly traded companies.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options to a director is a common compensation mechanism in the pharmaceutical and biotech sectors, similar to practices at companies like Moderna or Pfizer, which use equity to incentivize long-term performance.
• The vesting period of one year for RSUs and options, contingent on continued service, is a standard approach to ensure director retention and commitment, comparable to equity compensation plans observed at peer companies within the industry.
• An exercise price of $35.45 for options is typical for grants made at or around the market price on the grant date, reflecting a performance incentive tied to future stock appreciation, a common feature in executive and director compensation across the S&P 500.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term performance.
• Management: Reinforces the compensation structure for key leadership.

Next Steps

• Continued service by Louis G. Lange to ensure vesting of RSUs and stock options.
• Future reporting of beneficial ownership changes as required by Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to a director and a correction of a previous reporting error. While the grants align the director's interests with shareholders, they do not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The correction is a procedural matter. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing company fundamentals.

Keywords

NewAmsterdam Pharma, NAMS, Form 4, Insider Transaction, Louis G. Lange, Restricted Stock Units, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership